WELCOME 2017-11-20T20:36:25+00:00

Bexion Pharmaceuticals, Inc. Presents Clinical Data at 2018 SNO Annual Meeting

November 19th, 2018|0 Comments

FOR IMMEDIATE RELEASE Covington, KY, November 19, 2018 - Bexion Pharmaceuticals, Inc., a clinical - stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster [...]

Bexion Pharmaceuticals, Inc. Represented at 15 th Annual BioNetwork Partnering Summit

October 18th, 2018|0 Comments

National Cancer Institute (NCI) S elects Bexion as a Presenting Company FOR IMMEDIATE RELEASE Covington, KY ~ October 1 8 , 201 8 - Bexion Pharmaceuticals, Inc., a clini cal stage biotechnology company focused on developing [...]

Patient No. 1 and the cancer trial here that just might change everything

August 8th, 2018|0 Comments

Cincinnati Enquirer (Aug. 8, 2018) If you saw Bob Rulli on the street, you’d never guess he had cancer. He's the first person to receive a first-of-its-kind drug made in Cincinnati. (Photo: Kareem Elgazzar/The Enquirer) [...]

Bexion Pharmaceuticals is developing innovative cures for cancer.

Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.

Read More About Bexion
Clinical Trials

Clinical Trials

In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).

Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857